Evidence map›Paper›PMID 35121931›Full record

ArticleNature cancer2020

Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44.

Amy L Cummings, Jaklin Gukasyan, Henry Y Lu, Tristan Grogan, Gemalene Sunga, Charlene M Fares, Nicholas Hornstein, Jesse Zaretsky, James Carroll, Benjamin Bachrach and 11 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.1field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 47 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 1 institution in 1 country.

Amy L CummingsDepartment of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0003-0472-392X
Jaklin GukasyanDepartment of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.
Henry Y LuDepartment of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.
Tristan GroganDepartment of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.
Gemalene SungaDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.
Charlene M FaresDepartment of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-7003-5917
Nicholas HornsteinDepartment of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.
Jesse ZaretskyDepartment of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.
James CarrollDepartment of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.
Benjamin BachrachDepartment of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.
Wisdom O AkingbemiDepartment of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.
Debory LiDepartment of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-9820-2975
Zorawar NoorDepartment of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.
Aaron LisbergDepartment of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.
Jonathan W GoldmanDepartment of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.
David ElashoffDepartment of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.
Alex A T BuiDepartment of Radiology, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.
Antoni RibasDepartment of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0003-3669-8458
Steven M DubinettDepartment of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.
Maura RossettiDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.
Edward B GaronDepartment of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA. egaron@mednet.ucla.edu.ORCID http://orcid.org/0000-0001-7077-8801
University of California, Los Angeles · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
Project 3: Modeling and overcoming resistance to melanoma immunotherapyP01CA244118 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MORICEAU, GATIEN P · 2020 to 2024
$12.8M
Next Generation Cancer Immunotherapies to Defeat MelanomaR35CA197633 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTONI RIBAS · 2015 to 2026
$10.4M
UCLA Tumor Immunology Training ProgramT32CA009120 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Steven M. Dubinett, MICHAEL A TEITELL · 1985 to 2026
$10.3M
Integrated Molecular, Cellular, and Imaging Characterization of Screen-Detected Lung CancerU01CA196408 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ABERLE, DENISE R., DUBINETT, STEVEN M. · 2015 to 2021
$7.1M
A model for predicting response to PD-1 inhibitors in NSCLCR01CA208403 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GARON, EDWARD B · 2017 to 2021
$3.2M
Individually-tailored clinical decision support for management of indeterminate pulmonary nodulesR01CA226079 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ABERLE, DENISE R., BUI, ALEX · 2019 to 2023
$2.3M
Intratumoral Administration of CCL21-gene Modified Dendritic Cell With Intravenous Pembrolizumab for Advanced NSCLCK08CA245249 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LISBERG, AARON ELLIOTT · 2020 to 2024
$1.3M
Center for Strategic Scientific Initiatives, National Cancer Institute (NCI Center for Strategic Scientific Initiatives) R01 CA28403NCATS NIH HHS UL1 TR001881NCI NIH HHS K08 CA245249NCI NIH HHS P01 CA244118NCI NIH HHS P30 CA016042NCI NIH HHS R01 CA208403NCI NIH HHS R01 CA226079NCI NIH HHS R35 CA197633NCI NIH HHS T32 CA009120NCI NIH HHS U01 CA196408
6 · The paper itself

Abstract

Human leukocyte antigen (HLA)-B has been recognized as a major determinant of discrepancies in disease outcomes, and recent evidence indicates a role in immune checkpoint blockade (ICB) efficacy. The B44 supertype, which features an electropositive binding pocket that preferentially displays peptides with negatively charged amino acid anchors, is associated with improved survival in ICB-treated melanoma. Yet this effect was not seen in ICB-treated non-small-cell lung cancer (NSCLC). Here we show that mutations leading to glutamic acid substitutions occur more often in melanoma than NSCLC based on mutational landscape. We additionally show stratifying B44 based on the presence of somatic mutations that lead to negatively charged glutamic acid anchors identifies patients with NSCLC with an ICB benefit similar to that seen in melanoma. We anticipate these findings could improve assessment of HLA-related outcomes and prediction of ICB benefit in those with B44, representing approximately half of the world's population.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsMelanomaGlutamic AcidHLA-B44 AntigenHLA-B AntigensHumansImmunotherapyMutationGlutamic AcidHLA-B44 AntigenHLA-B Antigens

Identifiers

PMID35121931
PMCPMC12316451
OpenAlexW3104635171

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.